Caring for the human being as a whole
Pierre Fabre take a holistic approach to the care and treatment of people.
About Pierre Fabre:
With a portfolio representing a continuum of activities spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the second largest dermo-cosmetics laboratory in the world, the second largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several global brands and franchises, such as Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Naturactive, Pierre Fabre Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre Oncologie.
In 2018, Pierre Fabre generated 2.3 billion euros in revenue, of which 64% came from its international business and 61% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, has approximately 11,000 employees worldwide, owns subsidiaries and offices in 45 countries, and enjoys distribution agreements in over 130 countries. In 2018, Pierre Fabre dedicated 187 million euros to R&D efforts, split between oncology, consumer healthcare, dermatology and dermo-cosmetics.
Pierre Fabre is 86%-owned primarily by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.
In 2019, Ecocert Environment assessed the Group’s corporate social and environmental responsibility approach according to the ISO 26000 standard on sustainable development and awarded it the ECOCERT 26000 “Excellence” level.
BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib)
Encorafenib is an oral small-molecule BRAF kinase inhibitor, and binimetinib is an oral small-molecule MEK inhibitor, both of which target key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, non-small cell lung cancer, thyroid cancer and others.
For more information, please visit www.pierre-fabre.com.au.
Level 7, 32 Walker Street, North Sydney
NSW, 2060 Australia
BRAFTOVI in combination with cetuximab is the first and only targeted regimen approved in Australia specifically for metastatic colorectal cancer patients with a BRAFV600-mutation.(2,3) Pierre Fabre announced that BRAFTOVI (encorafenib) in combination with cetuximab is now PBS reimbursed to treat metastatic colorectal cancer (mCRC) patients with a BRAFV600 mutation following failure to respond to at least one prior systemic therapy.(1) Welcoming the news, Associate Professor Jayesh Desai, Medical Oncologist at the Peter MacCallum Cancer Centre and a lead investigator on the BEACON CRC trial said, “Patients will now have access, for the very first time, to a targeted therapy specifically…